# The Effect Of Fragmin In The Treatment Of Neuroischaemic Foot Ulcers In Diabetic Patients (A6301086)

> **NCT00765063** · PHASE2,PHASE3 · COMPLETED · sponsor: **Pfizer** · enrollment: 62 (actual)

## Conditions studied

- Diabetic Foot Ulcer

## Interventions

- **DRUG:** Fragmin

## Key facts

- **NCT ID:** NCT00765063
- **Lead sponsor:** Pfizer
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2,PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2008-10
- **Primary completion:** 2010-10
- **Final completion:** 2010-10
- **Target enrollment:** 62 (ACTUAL)
- **Last updated:** 2012-01-13


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00765063

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00765063, "The Effect Of Fragmin In The Treatment Of Neuroischaemic Foot Ulcers In Diabetic Patients (A6301086)". Retrieved via AI Analytics 2026-06-08 from https://api.ai-analytics.org/clinical/NCT00765063. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*